Original from: Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has categorized its Ionify® 25-Hydroxy Vitamin D total assay as “Moderate Complexity” under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This represents the first time a mass spectrometry-based test has achieved this designation, opening access to a broader range of clinical laboratories.

The assay runs on Roche’s cobas® i 601 analyzer, part of the cobas® Mass Spec solution. By combining mass spectrometry’s sensitivity and specificity with a standardized, easy-to-use workflow, the cobas® Mass Spec solution streamlines complex testing and reduces variability across labs. Traditionally, these tests have been confined to highly specialized labs due to complex workflows and the need for expert operators.

The Ionify 25-Hydroxy Vitamin D total assay is the first in Roche’s planned U.S. pipeline for the cobas® Mass Spec solution. Roche already offers a broad menu of mass spectrometry assays in countries accepting the CE mark, with additional launches anticipated globally.

Roche’s proprietary chemistry enables scalable automation with a workflow that is faster, more reproducible and more environmentally sustainable than conventional mass spectrometry methods. This reduces variability across labs and helps minimize the need for outsourcing advanced testing. 

Source: Roche achieves first CLIA ‘Moderate Complexity’ categorization for Ionify® 25-Hydroxy Vitamin D total test